

Special Issue

Gene Therapy

Message from the Guest Editor

Many gene therapy and genetic vaccine vectors are non-replicating agents. If they deliver one transgene to the cell, they then express $31X^2$ of the transgene protein. While replication-defective vectors can be potent, replication-competent vectors can surpass this potency by replicating transgenes in each cell to amplify therapeutic or vaccine responses. In many cases, apples and oranges comparisons of replication-defective and replication-competent vectors are performed. This issue will discuss vectors with and without replicating functions with particular emphasis on head to head comparisons of replication-defective, single-cycle, and replication-competent vectors.

Guest Editor

Dr. Michael A. Barry

Departments of Medicine, Immunology, and Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA

Deadline for manuscript submissions

closed (31 October 2016)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/6597

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2
(Genetics (clinical))